

Clara Natoli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1098345/clara-natoli-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156
papers

3,708
citations

30
h-index

53
g-index

164
ext. papers

4,252
ext. citations

5.3
avg. IF

4.43
L-index

#	Paper	IF	Citations
156	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. <i>Trends in Immunology</i> , 2002 , 23, 313-20	14.4	450
155	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
154	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties 2000 , 85, 545-554		150
153	90K (Mac-2 BP) and galectins in tumor progression and metastasis. <i>Glycoconjugate Journal</i> , 2002 , 19, 551-6	3	122
152	Prognostic value of a novel circulating serum 90K antigen in breast cancer. <i>British Journal of Cancer</i> , 1994 , 69, 172-6	8.7	107
151	Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. <i>FEBS Letters</i> , 2000 , 473, 311-5	3.8	106
150	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016 , 7, 19738-47	3.3	106
149	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. <i>Journal of Hepatology</i> , 1996 , 25, 212-7	13.4	72
148	Gynaecomastia with cimetidine. <i>Lancet, The</i> , 1977 , 1, 1319	40	69
147	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016 , 15, 1327-36	5.2	58
146	Triple positive breast cancer: a distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015 , 41, 69-76	14.4	56
145	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , 2019 , 44, 33-38	3.6	52
144	Hormone-modulated rRNA gene activity is visualized by selective staining of the NOs. <i>Cell Biology International Reports</i> , 1985 , 9, 791-6		50
143	What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. <i>Oncotarget</i> , 2015 , 6, 35589-601	3.3	49
142	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , 2013 , 91, 83-94	5.5	45
141	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. <i>Breast Cancer Research and Treatment</i> , 1988 , 11, 19-30	4.4	45
140	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 128, 17-26	7.5	41

139	Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. <i>FEBS Letters</i> , 1993 , 319, 59-65	3.8	41
138	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017 , 8, 56921-56931	3.3	41
137	Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. <i>Anticancer Research</i> , 2009 , 29, 403-10	2.3	41
136	Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. <i>Cancer Letters</i> , 2008 , 270, 229-33	9.9	40
135	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019 , 120, 57-62	8.7	40
134	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485	21.7	39
133	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. <i>Breast Cancer Research and Treatment</i> , 1983 , 3, 23-32	4.4	38
132	90K (Mac-2 BP) in human milk. <i>Clinical and Experimental Immunology</i> , 1996 , 104, 543-6	6.2	35
131	Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3850-6	2.2	34
130	Tyrosine kinase inhibitors. <i>Current Cancer Drug Targets</i> , 2010 , 10, 462-83	2.8	33
129	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 599-607	4.4	32
128	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000 , 96, 3282-3285	3.25	31
127	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. <i>Cancers</i> , 2013 , 5, 919-42	6.6	30
126	Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells. <i>International Journal of Cancer</i> , 1988 , 42, 182-4	7.5	30
125	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014 , 5, 9619-25	3.3	30
124	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 221-9	4.9	29
123	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. <i>International Journal of Cancer</i> , 1996 , 68, 34-8	7.5	29
122	Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections. <i>Clinical and Experimental Immunology</i> , 1999 , 115, 91-4	6.2	28

121	DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. <i>Cancer</i> , 1993 , 71, 1289-96	6.4	28
120	Interleukin-30 Promotes Breast Cancer Growth and Progression. <i>Cancer Research</i> , 2016 , 76, 6218-6229	10.1	27
119	A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. <i>AIDS Research and Human Retroviruses</i> , 1993 , 9, 811-6	1.6	27
118	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27
117	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016 , 7, 17932-44	3.3	26
116	90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. <i>International Journal of Cancer</i> , 1998 , 79, 23-6	7.5	25
115	Estrogen binding by neoplastic human thymus cytosol. <i>European Journal of Cancer</i> , 1980 , 16, 951-5		25
114	Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. <i>Cancer</i> , 2018 , 124, 2923-2930	6.4	24
113	An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. <i>Current Cancer Drug Targets</i> , 2012 , 12, 439-52	2.8	24
112	Glucocorticoids inhibit the stimulatory effect of epidermal growth factor on the initiation of DNA synthesis. <i>Journal of Cellular Physiology</i> , 1981 , 107, 155-63	7	24
111	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016 , 5, e1160187	7.2	24
110	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 107, 20-32	7	24
109	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 236	12.8	24
108	Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009 , 1795, 62-81	11.2	23
107	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. <i>International Journal of Cancer</i> , 2009 , 124, 333-8	7.5	22
106	Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. <i>Clinical Cancer Research</i> , 2006 , 12, 1501-6	12.9	22
105	Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. <i>Journal of Infectious Diseases</i> , 1991 , 164, 616-7	7	22
104	Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. <i>British Journal of Cancer</i> , 1993 , 67, 564-7	8.7	22

103	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920942378	5.4	22
102	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
101	Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. <i>Clinical Breast Cancer</i> , 2015 , 15, e131-7	3	21
100	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. <i>Journal of Pathology</i> , 2002 , 197, 218-23	9.4	21
99	The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 225, 617-20	3.4	21
98	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. <i>International Journal of Cancer</i> , 1994 , 59, 808-13	7.5	21
97	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 62	12.8	19
96	Tumor-derived microvesicles: the metastasomes. <i>Medical Hypotheses</i> , 2013 , 80, 75-82	3.8	19
95	Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study. <i>BMC Cancer</i> , 2017 , 17, 753	4.8	18
94	Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 229-37	3.8	18
93	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018 , 233, 2313-2323	7	17
92	Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. <i>Clinical and Experimental Immunology</i> , 1998 , 113, 394-400	6.2	17
91	Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. <i>Journal of Infectious Diseases</i> , 1991 , 164, 819	7	17
90	Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. <i>British Journal of Haematology</i> , 1993 , 85, 207-9	4.5	17
89	"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. <i>Oncotarget</i> , 2017 , 8, 23891-23904	3.3	17
88	Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. <i>Journal of Oncology</i> , 2019 , 2019, 5879616	4.5	17
87	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019 , 20, 192-200	4.6	17
86	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 269-80	4.9	16

85	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. <i>Breast</i> , 2016 , 29, 96-101	3.6	16
84	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019 , 10, 5926-5934	4.5	16
83	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019 , 234, 7708-7717	7	16
82	Unknown primary tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011 , 1816, 13-24	11.2	15
81	Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 187-90	4.3	15
80	Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. <i>OncoTargets and Therapy</i> , 2017 , 10, 3007-3015	4.4	14
79	Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 916-25	6.1	14
78	The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995 , 10, 450-6		14
77	Tamoxifen induced membrane alterations in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , 1984 , 20, 425-8		14
76	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 21259-71	3.3	14
75	Treatment of Metastatic Colorectal Cancer Patients ≥5 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016 , 11, e0157751	3.7	14
74	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 125-133	5.1	13
73	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015 , 6, 42773-80	3.3	13
72	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 279	12.8	12
71	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017 , 232, 15717-1578	7.1578	12
70	Body mass index modifies the relationship between γH2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017 , 17, 101	4.8	11
69	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020 , 235, 7900-7910	7	11
68	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016 , 231, 986-91	7	11

67	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017 , 7, 10597	4.9	11
66	A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 1015-20	10.3	11
65	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1013-9	4	11
64	Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. <i>Cancer Letters</i> , 1996 , 107, 143-8	9.9	11
63	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <i>Breast</i> , 2017 , 32, 79-86	3.6	10
62	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017 , 8, 54528-54536	3.3	10
61	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018 , 19, 328-334	4.6	10
60	Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1575-82	3.1	10
59	Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen. <i>International Journal of Cancer</i> , 1995 , 64, 130-4	7.5	10
58	Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , 1984 , 20, 747-52		10
57	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016 , 231, 2541-7	7	10
56	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties 2000 , 85, 545		10
55	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , 2018 , 10, 643-655	3.8	9
54	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 89	12.8	8
53	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. <i>Journal of Oncology Pharmacy Practice</i> , 2013 , 19, 246-53	1.7	8
52	Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1999 , 4, 151-62	5.4	8
51	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. <i>Cancer</i> , 1990 , 65, 1325-8	6.4	8
50	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , 2020 , 12, 59-67	1.8	8

49	90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. <i>Oncology Reports</i> , 1994 , 1, 723-5	3.5	8
48	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019 , 10, 5903-5914	4.5	8
47	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients Satisfaction. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 520-525	3.3	7
46	Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019 , 71, 181-184	4.4	7
45	Rivaroxaban for cancer-associated cardiac thrombosis. <i>American Journal of Medicine</i> , 2015 , 128, e43-4	2.4	6
44	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2365-2373	4.9	6
43	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1229-40	4.9	6
42	Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer. <i>Disease Markers</i> , 2013 , 35, 747-52	3.2	6
41	Prognostic value of a novel interferon-inducible 90K tumor antigen. <i>Annals of the New York Academy of Sciences</i> , 1996 , 784, 288-93	6.5	6
40	Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus. <i>Journal of Infection</i> , 1994 , 28, 31-9	18.9	6
39	A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995 , 18, 27-31	2.7	6
38	Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. <i>PLoS ONE</i> , 2014 , 9, e94063	3.7	6
37	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. <i>Oncotarget</i> , 2017 , 8, 69025-69037	3.3	6
36	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016 , 7, 35803-35812	3.3	6
35	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1704-9	4.6	5
34	Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. <i>Journal of Clinical Immunology</i> , 1999 , 19, 143-7	5.7	5
33	Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. <i>British Journal of Cancer</i> , 1992 , 66, 981-3	8.7	5
32	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , 2018 , 9, 241-252	3.2	4

31	Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. <i>Journal of Cancer</i> , 2015 , 6, 575-82	4.5	4
30	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. <i>Aids</i> , 2000 , 14, F41-5	3.5	4
29	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: evidence for differential mechanism of action on tumor cells in vitro. <i>Breast Cancer Research and Treatment</i> , 1985 , 6, 255-6	4.4	4
28	A multidisciplinary group for prostate cancer management: A single institution experience. <i>Oncology Letters</i> , 2018 , 15, 1823-1828	2.6	3
27	Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. <i>British Journal of Cancer</i> , 2004 , 91, 618-20	8.7	3
26	Growth inhibitory effects of thyroid hormones on androgen-dependent mammary tumor cells. <i>The Journal of Steroid Biochemistry</i> , 1981 , 15, 409-13		3
25	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , 2018 , 38, 3105-3110	2.3	3
24	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020 , 146, 1917-1929	7.5	3
23	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. <i>Minerva Urology and Nephrology</i> , 2021 , 73, 489-497	2.3	3
22	Cyclooxygenase-independent induction of p21WAF-1/CIP1, apoptosis and differentiation by L-745,337 and salicylate in HT-29 colon cancer cells. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 469, 555-61	3.6	3
21	A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 1018492	0.9	2
20	DNA ploidy and S-phase fraction in pulmonary carcinoids. <i>European Journal of Cancer</i> , 1992 , 28A, 1933-4	7.5	2
19	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000 , 96, 3282-3285	2	2
18	Tgf- β transcriptionally promotes 90K expression: possible implications for cancer progression. <i>Cell Death Discovery</i> , 2021 , 7, 86	6.9	2
17	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919853192	5.4	1
16	Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib. <i>International Medical Case Reports Journal</i> , 2020 , 13, 89-93	1	1
15	Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report. <i>International Medical Case Reports Journal</i> , 2017 , 10, 173-175	1	1
14	Effect of thyroid hormones on androgen responsiveness in a mammary tumor cell line. <i>The Journal of Steroid Biochemistry</i> , 1981 , 15, 415-9		1

13	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211059873	5.4	1
12	Predictive Ability for Disease-Free Survival of the GGrade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. <i>Current Urology</i> , 2020 , 14, 98-104	1.7	1
11	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , 2021 , 10,	7.9	1
10	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
9	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. <i>Journal of Human Genetics</i> , 2017 , 62, 379-387	4.3	0
8	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. <i>Breast</i> , 2017 , 35, 218-219 ³⁶		
7	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. <i>Tumori</i> , 2014 , 100, e309-e313	1.7	
6	Combinations of biological response modifiers: rationale and clinical responses. <i>Pharmacological Research</i> , 1992 , 26 Suppl 2, 102-3	10.2	
5	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥5 years (y) old in clinical practice: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14514-e14514	2.2	
4	Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A retrospective multicenter observational study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11542-e11542	2.2	
3	CAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21009-e21009	2.2	
2	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020 , 15, 22-27	2.4	
1	Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. <i>Recenti Progressi in Medicina</i> , 2020 , 111, 761-768	0.7	